Estimates from the US laboratory are skyrocketing over the months.
While last May, Pfizer planned to sell $ 26 billion in doses against the Coronavirus this year, it is once again revising this figure upwards.
It will ultimately be $ 33.5 billion worth of vaccines thanks to orders for 2.1 billion doses worldwide.
Last February, estimates counted on 15 billion sales for 2021 on this vaccine developed in partnership with the German BioNTech.
"The speed and efficiency of our efforts with BioNTech to help vaccinate the world against Covid-19 is unprecedented, with now more than a billion doses delivered globally," responded the CEO of the group, Albert Bourla, quoted in the press release for the second quarter.
Delta shouldn't drive down sales
Sales could grow further, as Pfizer / BioNTech advocates a third dose of its vaccine to make it more effective, at a time when the highly contagious Delta variant is causing epidemic outbreaks in Asia and Africa and pushing up the number of cases in Europe and in the USA.
The alliance spoke at the beginning of July of “encouraging results” of trials for a third dose and planned to seek authorization for a third dose of its vaccine, in the United States and in Europe.
On the strength of its rising sales, the company has logically raised its forecasts for annual turnover and profits.
It now anticipates for the whole of 2021 a turnover of between 78 billion and 80 billion dollars, against 70.5 billion to 72.5 billion dollars in May, carried by its sales of anti-vaccines. Covid who have already grossed $ 11.3 billion in the first six months of the year.
Earnings per share, which serves as a benchmark on Wall Street, could for its part grow from $ 3.95 to $ 4.05, against $ 3.55 to $ 3.65 initially expected.
In the second quarter alone, the group achieved a turnover of 18.9 billion dollars, almost double a year earlier (+ 92%) and above the expectations of analysts who were counting on 18, 45 billion.
Coronavirus in the United States: Washington orders 200 million additional doses of Pfizer-BioNTech vaccine
Coronavirus in Africa: Pfizer / BioNTech vaccine to be produced in Cape Town to supply continent from 2022